10x Genomics enters the post-earnings week with an unusual tension: short sellers are quietly rebuilding positions into a stock that just rocketed 22% in a single week, while analysts race to lift targets that the price has already blown through.
The short-covering story that defined the previous note has reversed in the past 48 hours. Short interest jumped 7% in a single session on August 11, adding more than a million shares to reach 16 million — back to 13.8% of free float, up from a recent low near 12.3%. That's still well below the July peak of 22.7 million shares, so this is not a full reversal of the unwind. But the direction has flipped. Some shorts that fled into the earnings beat are now rebuilding, likely betting the 22% weekly move has overshot. Borrow availability has tightened in step: availability dropped from 711% a week ago to 455% now — still comfortable in absolute terms, meaning more than four shares exist in the lending pool for every one shorted, and cost to borrow remains negligible at 0.44%. The lending market is not stressed. The rebuilding looks opportunistic rather than structural. Options add a layer of caution: the put/call ratio has climbed to 0.39, its highest reading in nearly a year and running two standard deviations above the 20-day average. That's not bearish outright, but it signals that hedging demand has picked up sharply alongside the price surge.
The Street response to last week's earnings beat has been unanimous in direction but divided in conviction. Every analyst who published in the past five days raised their price target — but the gap between where they're pointing and where the stock trades tells the real story. Stephens lifted to $65, now the highest target, and the stock at $58.48 has already passed the Canaccord $60 target raised on August 10. Morgan Stanley went to $40, maintaining Equal-Weight. Citigroup moved to $50, also Neutral. The consensus mean sits at $49.54 — a level the stock has already cleared. In other words, the majority of the Street is now technically below the current price while still maintaining neutral or positive ratings, a configuration that tends to produce further upgrades rather than downgrades. EPS momentum factor scores rank in the 95th and 96th percentiles over 30 and 90 days respectively, and the EPS surprise score sits at the 99th percentile — suggesting the beats have been consistent and material. The bear case rests on the 2024 revenue contraction from pricing pressure, a stock still down sharply from its 2021 peak, and valuation multiples that are difficult to defend: the price-to-earnings multiple is running above 430x on trailing earnings, and EV/EBITDA is negative. Bulls argue consumables volumes are accelerating and the recovery runway into 2027 is underappreciated.
The institutional register shows FMR (Fidelity) as the largest holder at 14.3% of shares, having added 5.8 million shares in the most recent reported period. ARK Investment Management holds 9%, adding modestly. Both are known as conviction holders in high-growth genomics names. Insider activity from the past three months runs the other direction: CEO Serge Saxonov sold roughly 30,000 shares across multiple June transactions at prices between $33 and $36 — well below current levels — alongside sales from the CSO and CFO in May. The significance scores on these trades are low, and the pattern looks like routine plan-based selling, not a directional signal. Still, at $58.48 the founders are sitting on stock they sold at a third less, which matters for future supply.
Correlated peers had a mixed week. BRKR gained 13% and Agilent added 7%, suggesting some sector-wide tailwind for life-science tools. PACB and QTRX each fell 20%+ on the week, illustrating that this rally remains stock-specific rather than a broad genomics re-rating.
The next scheduled earnings date is November 4. Between now and then, the key question is whether the analyst consensus — currently clustered below the stock price — catches up through upgrades, or whether the stock drifts back toward targets that the Street hasn't yet moved.
See the live data behind this article on ORTEX.
Open TXG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
